Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older who have been diagnosed with Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), or breast cancer
• People who are scheduled to receive chemotherapy that includes a high cumulative dose of a drug type called anthracyclines (at least 240 mg/m²)
• People whose heart pumping function (measured by a heart scan called an echocardiogram) is above 40% before starting chemotherapy
• People who have at least one of the following risk factors for heart problems from chemotherapy:
  • A history of blocked heart arteries, including previous procedures to open them (such as stenting or bypass surgery), or a significant blockage that was not treated with a procedure
  • A previous heart attack, provided heart pumping function remains above 40%
  • Heart pumping function between 41% and 54%
  • Age 65 or older
  • A previous diagnosis of high blood pressure (whether or not currently on medication)
  • Reduced kidney function (confirm specific measurement with trial site)
  • Currently smoking or having smoked in the past
  • Obesity, defined as a body mass index (BMI) of 30 or higher
  • An enlarged or thickened heart wall seen on the heart scan
  • High regular alcohol intake (21 or more alcoholic drinks per week)
  • A normal heart rhythm (called sinus rhythm) confirmed by a heart tracing (ECG)
  • A previous diagnosis of diabetes, except for people who take a certain type of diabetes medication called sulfonylureas, or who have diabetes-related nerve damage
  • Previous chemotherapy that did not include anthracyclines
• People who have read and signed the study consent form

Who may not be able to join:

• People who have previously received anthracycline chemotherapy for any cancer diagnosis
• People who have previously been diagnosed with heart failure
• People who have permanent atrial fibrillation (an irregular heart rhythm that does not return to normal)
• People with severe disease affecting the heart valves or structures just below the valves
• People with severe blood vessel disease in the upper arms, or a surgical connection between an artery and vein in the arm that would be used during the study procedure
• People who have been diagnosed with diabetes-related nerve damage (diabetic neuropathy)
• People with severe claustrophobia (as the study involves an MRI scan)
• People who have any implanted device or metal that is not safe in an MRI environment (confirm specific devices with the trial site)
• People who have an implanted heart device such as a pacemaker, defibrillator (ICD), or cardiac resynchronisation therapy (CRT) device
• People who have had a very low platelet count (a blood clotting cell) in the past three months
• People who are already participating in another clinical trial
• People who are unable to give consent or attend the required study follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.